​
​

Achieve Life Sciences Stock (NASDAQ:ACHV)

ForecastOwnershipFinancialsChartTranscripts
Achieve Life Sciences by TradingView

Previous Close

$4.43

52W Range

$3.03 - $5.98

50D Avg

$4.58

200D Avg

$4.59

Market Cap

$153.85M

Avg Vol (3M)

$228.36K

Beta

1.57

Div Yield

-

ACHV Company Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

22

IPO Date

Oct 12, 1995

Website

ACHV Performance

ACHV Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-27.25M$-40.80M$-33.09M
Net Income$-29.82M$-41.88M$-32.90M
EBITDA$-27.02M$-40.80M$-33.09M
Basic EPS$-1.50$-3.95$-4.05
Diluted EPS$-1.50$-3.95$-4.05

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q2 24Aug 14, 24 | 4:58 AM
Q1 24May 09, 24 | 7:58 PM
Q4 23Mar 28, 24 | 9:03 PM

Peer Comparison

TickerCompany
GRCLGracell Biotechnologies Inc.
XFORX4 Pharmaceuticals, Inc.
CNSPCNS Pharmaceuticals, Inc.
VECTVectivBio Holding AG
NXTCNextCure, Inc.
TCRXTScan Therapeutics, Inc.
APLSApellis Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
CTMXCytomX Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
AVROAVROBIO, Inc.
BOLTBolt Biotherapeutics, Inc.
INZYInozyme Pharma, Inc.
ASMBAssembly Biosciences, Inc.
IMMXImmix Biopharma, Inc.
ABOSAcumen Pharmaceuticals, Inc.
ITOSiTeos Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.
NLTXNeurogene Inc.
CHRSCoherus BioSciences, Inc.